Foghorn Therapeutics Q2 2025 net loss narrows to $17.9M; cash runway into 2028; pipeline on track

Foghorn Therapeutics Inc.

2025-Q2 EPS reported -$0.58 revenue$13,509,000

Net loss of $17.9M in Q2 2025, improved from $23.0M in Q2 2024; collaboration revenue $7.6M.
Cash, equivalents and marketable securities $198.7M as of June 30, 2025; cash runway into 2028.
FHD-909 Phase 1 trial in SMARCA4-mutated NSCLC enrolling well; preclinical combo data with pembrolizumab and KRAS inhibitors.
Selective CBP degrader targeting IND in 2026; selective EP300 and ARID1B degrader updates expected Q4 2025.
R&D expenses decreased to $21.8M from $23.8M; G&A expenses decreased to $6.9M from $7.3M.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.